Who are Ribociclib + Letrozole OR Fulvestrant's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ribociclib-letrozole-or-fulvestrant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ribociclib + Letrozole OR Fulvestrant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ribociclib + Letrozole OR Fulvestrant (Ribociclib + Letrozole OR Fulvestrant) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK4/6 inhibitor + aromatase inhibitor OR estrogen receptor degrader. Area: Oncology.

phase 3 CDK4/6 inhibitor + aromatase inhibitor OR estrogen receptor degrader CDK4/6 + aromatase OR estrogen receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ribociclib + Letrozole OR Fulvestrant (Ribociclib + Letrozole OR Fulvestrant) — SOLTI Breast Cancer Research Group. Ribociclib inhibits CDK4/6 to block cell cycle progression, combined with either letrozole (aromatase inhibitor) or fulvestrant (estrogen receptor antagonist) to suppress hormone-driven breast cancer growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ribociclib + Letrozole OR Fulvestrant TARGET	Ribociclib + Letrozole OR Fulvestrant	SOLTI Breast Cancer Research Group	phase 3	CDK4/6 inhibitor + aromatase inhibitor OR estrogen receptor degrader	CDK4/6 + aromatase OR estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK4/6 inhibitor + aromatase inhibitor OR estrogen receptor degrader class)

SOLTI Breast Cancer Research Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ribociclib + Letrozole OR Fulvestrant — Competitive Intelligence Brief. https://druglandscape.com/ci/ribociclib-letrozole-or-fulvestrant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab